CADL Retail Bulls See Buyout Potential As Key Cancer Data Catalyst Approaches

• Candel is set to submit a Biologics License Application to the U.S. Food and Drug Administration by the fourth quarter of 2026.
• The Phase 3 trial, which met its primary endpoint, included 745 patients.
• The company also expects to present additional biomarker data by the third quarter of 2026.

Shares of Candel Therapeutics (CADL) climbed 3% higher in pre-market trading on Friday, lifted by growing investor optimism ahead of a closely watched presentation of pivotal follow-up data for its prostate cancer therapy at the American Urological Association (AUA) 2026 Annual Meeting Plenary Program.

On Thursday, the biotech firm posted a first-quarter (Q1) loss of $0.14 per share, compared to consensus estimates of a loss of $0.33 per share, according to Fiscal.ai data.

All Eyes On CADL’s Phase 3 Follow-Up Data

Candel is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene (CAN-2409) in patients with localized, intermediate- to high-risk prostate cancer, and also announced plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the treatment by the fourth quarter of 2026.

A BLA is a formal request to allow for the marketing and sales of a therapy in the United States.

In the third quarter of 2026, the company expects to present additional biomarker data. The drug has already been granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations by the U.S. Food and Drug Administration (FDA).

What Did Phase 3 Results Show?

In December 2024, Candel reported positive Phase 3 results for its CAN-2409 therapy. The study met its primary endpoint, showing that patients who received the drug along with standard treatment stayed disease-free longer than those on standard care alone.

The trial was randomized, double-blind, placebo-controlled, and included 745 patients. The goal was to improve disease-free survival in patients with intermediate- to high-risk localized prostate cancer.

Retail’s Take On CADL’s Presentation

Retail sentiment for CADL on Stocktwits remained in the ‘bullish’ zone, while message volumes on the platform surged more than 130% over a 24-hour period.

One user expects the readout to be “significant,” as it could show a lower hazard ratio and potentially speed up the drug’s approval process.

Another user said that regardless of Friday’s outcome, the company’s market capitalization could more than double by the time Candel submits its BLA, potentially paving the way for a future acquisition.

CADL shares have gained around 50% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.